

Sepehr Shakib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5841124/publications.pdf>

Version: 2024-02-01

87
papers

3,193
citations

331670
21
h-index

161849
54
g-index

93
all docs

93
docs citations

93
times ranked

4572
citing authors

#	ARTICLE	IF	CITATIONS
1	What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 2017, 17, 230.	2.7	1,706
2	Development and Validation of the Revised Patientsâ€™ Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. Drugs and Aging, 2016, 33, 913-928.	2.7	131
3	Polypharmacy cut-points in older people with cancer: how many medications are too many?. Supportive Care in Cancer, 2016, 24, 1831-1840.	2.2	109
4	What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open, 2016, 6, e009781.	1.9	92
5	The benefits and harms of deprescribing. Medical Journal of Australia, 2014, 201, 386-389.	1.7	72
6	Feasibility of a Patient-Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors. Annals of Pharmacotherapy, 2015, 49, 29-38.	1.9	65
7	Precision dosing in clinical medicine: present and future. Expert Review of Clinical Pharmacology, 2018, 11, 743-746.	3.1	60
8	Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels. Internal Medicine Journal, 2017, 47, 1292-1297.	0.8	54
9	Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review. Drugs and Aging, 2018, 35, 43-60.	2.7	53
10	Major bleeding risk associated with warfarin and coâ€medications in the elderly population. Pharmacoepidemiology and Drug Safety, 2011, 20, 1057-1063.	1.9	47
11	Potentially inappropriate medication use in older people with cancer: Prevalence and correlates. Journal of Geriatric Oncology, 2014, 5, 439-446.	1.0	46
12	Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers. American Journal of Clinical Dermatology, 2016, 17, 519-526.	6.7	42
13	Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure, 2019, 25, 744-756.	1.7	38
14	Hospital admissions caused by adverse drug events: an Australian prospective study. Australian Health Review, 2014, 38, 51.	1.1	36
15	Uptake of novel oral anticoagulants in Australia. Medical Journal of Australia, 2016, 204, 104-105.	1.7	32
16	Risk factors for deaths during the 2009 heat wave in Adelaide, Australia: a matched case-control study. International Journal of Biometeorology, 2017, 61, 35-47.	3.0	31
17	A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. Cancer Epidemiology, 2019, 63, 101590.	1.9	31
18	Heart failure after conventional metal-on-metal hip replacements. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 2-9.	3.3	28

#	ARTICLE	IF	CITATIONS
19	Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine, 2016, 34, 3156-3163.	3.8	27
20	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 2020, 11, 114-120.	1.0	27
21	Guideline Compliance in Chronic Heart Failure Patients with Multiple Comorbid Diseases: Evaluation of an Individualised Multidisciplinary Model of Care. PLoS ONE, 2014, 9, e93129.	2.5	23
22	Is my older cancer patient on too many medications?. Journal of Geriatric Oncology, 2017, 8, 77-81.	1.0	22
23	Feasibility and Timeliness of Alternatives to Post-Discharge Home Medicines Reviews for High-Risk Patients. Journal of Pharmacy Practice and Research, 2011, 41, 27-32.	0.8	21
24	Role of the Pharmacist for Improving Self-care and Outcomes in Heart Failure. Current Heart Failure Reports, 2017, 14, 78-86.	3.3	20
25	Understanding 30-day readmission after hospitalisation of older patients for diabetes: identifying those at greatest risk. Medical Journal of Australia, 2017, 206, 170-175.	1.7	20
26	Effect of a Multidisciplinary Outpatient Model of Care on Health Outcomes in Older Patients with Multimorbidity: A Retrospective Case Control Study. PLoS ONE, 2016, 11, e0161382.	2.5	20
27	Risk factors of direct heat-related hospital admissions during the 2009 heatwave in Adelaide, Australia: a matched case-control study. BMJ Open, 2016, 6, e010666.	1.9	19
28	The nasal airways response in normal subjects to oxymetazoline spray: randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 1999, 48, 53-56.	2.4	18
29	Categorization of adverse drug reactions in electronic health records. Pharmacology Research and Perspectives, 2020, 8, e00550.	2.4	18
30	Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. Patient Preference and Adherence, 2017, Volume 11, 131-140.	1.8	16
31	Adverse drug reaction classification by health professionals: appropriate discrimination between allergy and intolerance?. Clinical and Translational Allergy, 2019, 9, 18.	3.2	16
32	Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review. Current Cardiology Reviews, 2016, 12, 180-185.	1.5	14
33	Classification of Findings in the Home Medicines Reviews of Post-Discharge Patients at Risk of Medication Misadventure. Journal of Pharmacy Practice and Research, 2007, 37, 111-114.	0.8	13
34	Rehospitalizations for complications and mortality following pacemaker implantation: A retrospective cohort study in an older population. Clinical Cardiology, 2018, 41, 1480-1486.	1.8	12
35	Automation of penicillin adverse drug reaction categorisation and risk stratification with machine learning natural language processing. International Journal of Medical Informatics, 2021, 156, 104611.	3.3	12
36	Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial. Vaccine, 2016, 34, 4991-4997.	3.8	11

#	ARTICLE	IF	CITATIONS
37	Predictors of Mortality in the Older Population: The Role of Polypharmacy and Other Medication and Chronic Disease-Related Factors. <i>Drugs and Aging</i> , 2020, 37, 767-776.	2.7	11
38	Factors associated with use of falls riskâ€“increasing drugs among patients of a geriatric oncology outpatient clinic in Australia: a crossâ€“sectional study. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 361-368.	1.8	10
39	The Australian Centre For Evidence-based Clinical Practice Generic Audit Tool: Auditmaker for health professionals. <i>Journal of Evaluation in Clinical Practice</i> , 2003, 9, 259-263.	1.8	9
40	Concomitant prescribing of opioids and benzodiazepines in Australia, 2012â€“2017. <i>Medical Journal of Australia</i> , 2019, 210, 39-40.	1.7	9
41	Caveat anicula! Beware of quiet little old ladies. <i>Medical Journal of Australia</i> , 2010, 192, 9-13.	1.7	8
42	Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. <i>BMJ Open</i> , 2019, 9, e026486.	1.9	8
43	Documentation of adverse drug reactions to opioids in an electronic health record. <i>Internal Medicine Journal</i> , 2021, 51, 1490-1496.	0.8	8
44	Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 157-164.	2.4	8
45	Use of Medicines that May Exacerbate Heart Failure in Older Adults: Therapeutic Complexity of Multimorbidity. <i>Drugs and Aging</i> , 2019, 36, 471-479.	2.7	7
46	Timeliness and Clinical Impact of Hospitalâ€“Initiated Medication Reviews. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 269-273.	0.8	6
47	Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing?. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 113-121.	2.4	6
48	Use of non-formulary high-cost medicines in an Australian public hospital. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 920-931.	2.1	6
49	A pilot cohort study of deprescribing for nursing home patients acutely admitted to hospital. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861985487.	2.4	6
50	Comprehension and recall from the informed consent process by phase I healthy volunteers before dose administration. <i>Clinical Trials</i> , 2019, 16, 283-289.	1.6	6
51	Prevalence of drug allergy in South Australia. <i>Internal Medicine Journal</i> , 2022, 52, 1957-1961.	0.8	6
52	A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 727-739.	3.5	6
53	Magnetic Resonance Imaging in People With Cardiac Implantable Electronic Devices: A Population Based Cohort Study. <i>Heart Lung and Circulation</i> , 2018, 27, 748-751.	0.4	5
54	Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 104.	1.7	5

#	ARTICLE	IF	CITATIONS
55	Analgesic Use and Pain in Robust, Pre-Frail and Frail Older Outpatients with Cancer. <i>Drugs - Real World Outcomes</i> , 2015, 2, 117-121.	1.6	4
56	External validation of beta-lactam antibiotic allergy assessment tools: implications for clinical practice and workforce capacity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2094-2095.	3.8	4
57	Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , 2020, 11, 128-130.	1.0	4
58	A Tool for Evaluating Medication Alerting Systems: Development and Initial Assessment. <i>JMIR Medical Informatics</i> , 2021, 9, e24022.	2.6	4
59	Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 425-435.	2.1	4
60	Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. <i>Blood</i> , 2018, 132, 3101-3101.	1.4	4
61	Precision medicine technology hype or reality? The example of computer-guided dosing. <i>F1000Research</i> , 2019, 8, 1709.	1.6	4
62	<i>S. aureus</i> colonization in healthy Australian adults receiving an investigational <i>S. aureus</i> 3-antigen vaccine. <i>Journal of Infection</i> , 2019, 79, 582-592.	3.3	3
63	Concomitant inpatient prescribing of strong opioids with sedatives: Associations with comorbid conditions. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00717.	2.4	3
64	Prospective cohort study of nonspecific deprescribing in older medical inpatients being discharged to a nursing home. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110523.	2.4	3
65	Prescribing: what's all the fuss?. <i>Australian Family Physician</i> , 2003, 32, 35-8.	0.5	3
66	Alternatives to Post-Discharge Home Medication Reviews for High-Risk Patients: Doctors' and Pharmacists' Views. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 273-277.	0.8	2
67	First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 234-245.	1.6	2
68	Frailty and Co-Prescribing of Potentially Interacting Drugs in New Users of Warfarin. <i>Drugs and Aging</i> , 2020, 37, 373-382.	2.7	2
69	Predictors of unplanned hospitalisation in the older population: The role of polypharmacy and other medication and chronic disease-related factors. <i>Australasian Journal on Ageing</i> , 2020, 39, e436-e446.	0.9	2
70	Attitudes of healthy volunteers to genetic testing in phase 1 clinical trials. <i>F1000Research</i> , 2021, 10, 259.	1.6	2
71	Diagnosis and therapeutic goals. What are you actually treating?. <i>Australian Family Physician</i> , 2003, 32, 147-9.	0.5	2
72	Monitoring: to infinity and beyond!. <i>Australian Family Physician</i> , 2003, 32, 995-7.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Pre-Admission and Post-Hospital Management of Heart Failure in Patients not Enrolled in Specialist Programs. Journal of Pharmacy Practice and Research, 2009, 39, 186-191.	0.8	1
74	Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study. Pain Management, 2017, 7, 243-253.	1.5	1
75	Electronic medication management: enthusiasm justified but caution required. Journal of Pharmacy Practice and Research, 2017, 47, 85-86.	0.8	1
76	Development and Implementation of a Nurse-Led Model of Care Coordination to Provide Health-Sector Continuity of Care for People With Multimorbidity: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2019, 8, e15006.	1.0	1
77	Writing the prescription and informing the patient. Australian Family Physician, 2003, 32, 702-4.	0.5	1
78	Survey of Clopidogrel Use in a Teaching Hospital. Journal of Pharmacy Practice and Research, 2006, 36, 40-43.	0.8	0
79	Use of benzodiazepines and risk of dementia over a 15-year follow-up period. Aging Health, 2013, 9, 73-75.	0.3	0
80	Cardiac Implantable Electronic Devices: Reoperations and the Competing Risk of Death. Heart Lung and Circulation, 2022, 31, 537-543.	0.4	0
81	Therapeutic approach: how to get there. Australian Family Physician, 2003, 32, 243-6.	0.5	0
82	Which drug class and why?. Australian Family Physician, 2003, 32, 325-8.	0.5	0
83	Choosing a drug from within a class. Australian Family Physician, 2003, 32, 438-41.	0.5	0
84	Individualising therapy. The right dose, dosage form, frequency and duration. Australian Family Physician, 2003, 32, 504-7.	0.5	0
85	Check suitability, minimise sue-ability!. Australian Family Physician, 2003, 32, 621-4.	0.5	0
86	Introduction to monitoring. What is what you prescribed actually doing?. Australian Family Physician, 2003, 32, 843-5, 864.	0.5	0
87	Monitoring in high level care. Australian Family Physician, 2003, 32, 905-8.	0.5	0